ABT Abbott Laboratories
Abbott Laboratories (ABT) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 9 comparable calls have settled; 22.2% reached the published sell target. Information only, not financial advice.
Broken out above, falling on both timeframes
Price has closed above the channel. The fitted trend may no longer describe this stock.
The next few months are read from the last 12 months, not the last 18 months: that channel fits this stock's recent turns at least as well (60% against 61%) and it is the one price is respecting now. The last 18 months stay as context: falling, −18% a year. The target of US$112.99 is below the nearest ceiling (US$116.49), so it does not depend on a breakout. What would overturn this: a close below US$60.08 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 18 months
- US$94.45 – US$116.49 Falling channel, −18% a year
- 12 months read from
- US$60.08 – US$73.62 Falling channel, −32% a year
- Position in that channel
- 312% above the ceiling of it — 0% is the floor, 100% the ceiling
What broke this trend
- The fall
- -40% from US$135.813 Mar 2025 → 11 May 2026
- Whose problem it was
- This company0 of 1 Medical - Devices peers fell with it
- Does it resolve?
- Temporary falls like it have resolved on the record
- Regained so far
- 37%of what it lost
- What the record says
- 78% of 936 comparable falls came back, typically in 86 days measured across every stock we hold history for, its peer group being too small
The trend broke in March 2025: price fell 40% from 135.81 to 81.97 by May 2026, and has regained 37% of that fall since. Its peers did not fall with it, so this was about the company rather than its sector. The wire that week: “What Does the Market Think About Abbott Laboratories?”. Falls like it have resolved: falls of about 40% here have come back to the old high 78% of the time (936 comparable falls), typically in 86 days. On that record the fall is treated as temporary, and the trend lines are fitted to the regime it created rather than through it. Priced from that: 137.63 within 227 days, reached 78% of the time in 936 comparable falls — about 0.15% a day held.
Reported at the time: What Does the Market Think About Abbott Laboratories? — 28 Feb 2025
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (18 months)
- Lower trend line (18 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
We replayed these rules over this stock's own history and the target was reached on only 2 of 9 calls. Its swings do not respect the channel reliably enough for a published call, and no alerts are sent. The numbers below are still this site's read of the fitted channel.
Buy now
US$102.37
last close · 16 Sept 2026
Channel buy is US$102.72; last close is the better price available now.
Our target
US$112.99
by 30 Oct 2026
Projected move
10.4%
gross, before costs
Last close is our buy — the best price available now.
On this stock's own history these rules produced 9 settled calls, of which 2 reached target (22.2%), with an average best move of 6.1%. See the full record.
- Upper line touches
- 7
- Lower line touches
- 2
- Fit confidence
- 61%
- Fitted
- 16 Sept 2026
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford
- Employees
- 115,000
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$177.12B
- Enterprise value
- —
- Beta
- 0.59
- Avg volume
- 11.22M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 81.97-137.49
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.